Cargando…
Treatment and secondary prevention of venous thromboembolism in cancer
Patients with cancer who develop venous thromboembolism (VTE) are at elevated risk for recurrent thrombotic events, even during anticoagulant therapy. The clinical picture is further complicated because these patients are also at increased risk of bleeding while on anticoagulants. In general, there...
Autores principales: | Coleman, R, MacCallum, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317403/ https://www.ncbi.nlm.nih.gov/pubmed/20386545 http://dx.doi.org/10.1038/sj.bjc.6605601 |
Ejemplares similares
-
Prevention and treatment of venous thromboembolism
por: Casadei, Barbara, et al.
Publicado: (2020) -
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
por: Stevanović, J., et al.
Publicado: (2016) -
Guidance for the prevention and treatment of cancer-associated venous thromboembolism
por: Khorana, Alok A., et al.
Publicado: (2016) -
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020) -
Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding
por: MacLehose, Richard F., et al.
Publicado: (2021)